Michelle Treitel
Overview
Explore the profile of Michelle Treitel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
92
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wei L, Wang F, Zhang M, Jia J, Yakovlev A, Xie W, et al.
World J Gastroenterol
. 2018 Mar;
24(12):1361-1372.
PMID: 29599611
Aim: To assess daclatasvir plus asunaprevir (DUAL) in treatment-naïve patients from mainland China, Russia and South Korea with hepatitis C virus (HCV) genotype 1b infection. Methods: Patients were randomly assigned...
2.
Kao J, Yu M, Peng C, Heo J, Chu C, Chang T, et al.
J Gastroenterol Hepatol
. 2017 Apr;
32(12):1998-2005.
PMID: 28370350
Background And Aim: This multinational (Taiwan, South Korea, Russia) phase 3 study evaluated the all-oral, ribavirin-free, fixed-dose combination (DCV-TRIO) of daclatasvir (NS5A inhibitor) 30 mg, asunaprevir (NS3 inhibitor) 200 mg,...
3.
Rodriguez-Torres M, Lawitz E, Yangco B, Jeffers L, Han S, Thuluvath P, et al.
Ann Hepatol
. 2016 Oct;
15(6):834-845.
PMID: 27740516
Material And Methods: In this single-arm, open-label study, 246 patients received daclatasvir plus pegIFN alfa-2a and weight-based RBV. Patients with an extended rapid virologic response (eRVR; undetectable HCV-RNA at treatment...
4.
Wei L, Zhang M, Xu M, Chuang W, Lu W, Xie W, et al.
J Gastroenterol Hepatol
. 2016 Mar;
31(11):1860-1867.
PMID: 27003037
Background And Aim: Daclatasvir plus asunaprevir has demonstrated efficacy and safety in patients with chronic hepatitis C virus genotype 1b infection. This study focused on evaluating daclatasvir plus asunaprevir in...
5.
Hezode C, Alric L, Brown A, Hassanein T, Rizzetto M, Buti M, et al.
Antivir Ther
. 2015 Aug;
21(3):195-205.
PMID: 26313445
Background: Treatment options for HCV genotype-4 (GT4) are limited. This Phase III study (COMMAND-4; AI444-042) evaluated the efficacy and safety of daclatasvir (DCV), a pan-genotypic HCV NS5A inhibitor, with pegylated...
6.
Vierling J, Davis M, Flamm S, Gordon S, Lawitz E, Yoshida E, et al.
J Hepatol
. 2013 Dec;
60(4):748-56.
PMID: 24362076
Background & Aims: Boceprevir with peginterferon/ribavirin (BOC/PR) leads to significantly higher sustained virological response (SVR) rates in patients with chronic hepatitis C and partial response or relapse after prior treatment...
7.
Silva M, Treitel M, Graham D, Curry S, Frontera M, McMonagle P, et al.
J Hepatol
. 2013 Mar;
59(1):31-7.
PMID: 23454058
Background & Aims: To examine the antiviral activity of boceprevir, a hepatitis C virus (HCV) protease inhibitor, in HCV genotype (G) 2/3-infected patients. Methods: We assessed boceprevir and telaprevir activity...
8.
Treitel M, Marbury T, Preston R, Triantafyllou I, Feely W, OMara E, et al.
Clin Pharmacokinet
. 2012 Jul;
51(9):619-28.
PMID: 22799589
Background And Objective: Boceprevir is a novel inhibitor of the hepatitis C virus NS3 protease and was recently approved for the treatment of patients with chronic hepatitis C infection. The...
9.
Fatkenheuer G, Hoffmann C, Slim J, Rouzier R, Keung A, Li J, et al.
J Acquir Immune Defic Syndr
. 2009 Oct;
53(1):78-85.
PMID: 19838130
Objective: CCR5 antagonists block HIV cell entry through competitive binding to the CCR5 receptor present on the surface of CD4(+) cells. The CCR5 receptor is also present on CD8(+) cells...